Welcome to Ocumel Canada

 

Ocumel Canada, an initiative of Save Your Skin Foundation, was formed to increase awareness, advance treatment options, and build a supportive community for those diagnosed with primary and/or metastatic ocular melanoma (OM). Ocumel Canada is in close collaboration with a global Medical Advisory Board and partner patient representation organizations with the endeavour to build on international best practices to improve patient outcomes for Canadians touched by this disease.

 

We envision a future when ocular melanoma will be a treatable and manageable disease and where patients in Canada can easily find support and courage after diagnosis.

Find helpful support and information here about ocular melanoma

This rare cancer is a challenge in so many ways. The small number of diagnoses in Canada does make it difficult for the mainstream Cancer Agencies to provide adequate services. In some provinces and territories, there are no services at all.

 

In 2020, Ocumel Canada surveyed Health Care Providers to assess the services currently provided by centres working in the ocular melanoma treatment landscape.  We are now working with multiple OM Patient Care Providers across the country to address gaps in the system and advocate for standardized care and improved access to treatment and clinical trials in Canada.

And in Spring 2021 we conducted an ocular melanoma patient/caregiver survey to assess the patient experience as it is today, across Canada.  Please click here to view the full survey report:

 

Ocumel Canada Patient Survey Report – Updating the OM Care Landscape in Canada, 2021

 

Click HERE to read about all of our 2018-2020 activity and work across Canada

 

A warm thank you to Save Your Skin Foundation for hosting this space. Staff are already knowledgeable and skilled in providing help to Canadians diagnosed with cutaneous melanoma and their experiences in building a powerful support group are our foundation.  View the following pages to find up-to-date links and resources:

Ocumel Canada – About Ocular Melanoma

Ocumel Canada – Helpful Links

Ocumel Canada – Resources and Support

 

Contact us at ocumelcanada@saveyourskin.ca or 1-800-460-5832

Ocular Melanoma – Watch our webinar Recorded February-2019 

With Dr. Marcus Butler, Princess Margaret Cancer Centre, Toronto, Canada  &              Dr. Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, California

This webinar provides an update on the landscape of metastatic ocular melanoma treatment in Canada and the United States. Dr. Hamid and Dr. Butler share their knowledge of current practices and care pathways, identifying the most pressing needs for patients.  They also discuss new and emerging treatment options such as IMCgp100 (now named Tebentafusp), as well as clinical trials available to Canadian patients with ocular or uveal melanoma.

With Thanks to our Supporters, including:

If you or someone you know has been diagnosed with primary or metastatic ocular melanoma, connect with our community of support, Canadian bilingual Facebook group:  Ocular Melanoma Connect/Connexion mélanome oculaire 

OM Connect

Click HERE to support Ocumel Canada with the purchase of a t-shirt:

Click to download a pdf version of the Ocumel Canada 2021 Strategic Plan:

OC_horizontal_blue

Listed above are a few sources of information and support you might find useful. These groups are not connected to Save Your Skin Foundation. We are providing the links as useful sources of information but do not monitor content for accuracy and quality.

NOTE: The information on the Save Your Skin Foundation website is not intended to replace the medical advice of a doctor or healthcare provider. While we make every effort to ensure that the information on our site is as current as possible, please note that information and statistics are subject to change as new research and studies are published. 

Making awareness and education available is crucial. Since 2006, the Foundation has worked to raise awareness of melanoma and non-melanoma skin cancers, and ocular melanoma, focusing on the need for improved patient care.
Show Buttons
Hide Buttons